Vanta Attends 2026 All-In Summit in Los Angeles

Vanta Holdings Inc., a consumer health sciences and longevity company, attended the 2026 All-In Summit in Los Angeles, a leading gathering of business, investment, and industry leaders. The summit, held from September 13-15, 2026, at the Shrine Auditorium and Expo Hall, attracted more than 2,500 attendees.

Vanta representatives engaged with founders, investors, executives, entrepreneurs, and industry participants across sectors aligned with the company’s broader growth strategy, including healthcare, biotechnology, and technology. These discussions provided opportunities to establish new relationships, exchange perspectives on emerging technologies and market developments, and explore potential areas of strategic collaboration and business development.

The company’s participation allowed representatives to engage with individuals and organizations across the peptide therapeutics and broader healthcare ecosystem, in connection with Vanta’s planned entry into the U.S. peptide market. As previously disclosed, the company is advancing a contemplated U.S.-focused peptide therapy platform designed to integrate telehealth-enabled patient acquisition, physician consultation, and prescription authorization workflows, FDA-registered compounding pharmacy fulfillment, compliant payment processing infrastructure, and subscription-based commercialization initiatives.

Vanta believes the relationships established at the All-In Summit complement the company’s broader efforts to expand its network across the healthcare, technology, investment, and entrepreneurial communities. The company intends to continue evaluating strategic relationships, emerging technologies, and business opportunities that may support its existing operations and long-term growth initiatives.

Martino Ciambrelli, Director of Vanta Holdings Inc., stated, “The All-In Summit brought together an exceptional cross-section of founders, investors, executives, and industry leaders across sectors that are increasingly relevant to Vanta’s long-term strategy. Our participation allowed us to establish meaningful new relationships across healthcare and technology, including within the U.S. peptide therapy ecosystem, while opening discussions around potential strategic collaboration and business development opportunities. We look forward to building on these relationships as we continue to advance Vanta’s growth strategy and expand our presence in the United States.”

Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC, WKN:A4205J) is a consumer health sciences and longevity company advancing an integrated ecosystem of U.S.-focused peptide therapy, nutraceutical, and premium hydration products centered on preventative wellness and healthspan extension, positioning the company to participate in the rapidly expanding longevity economy.